Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?

Click to increase image sizeClick to decrease image size

Declaration of interest

H Miyamoto has received research funding from Astellas Scientific and Medical Affairs, Ferring Research Institute, and Bristol-Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

A peer reviewer has disclosed that they are currently Chair of the ANZUP BUP subcommittee, have served as remunerated Chair of recent Expert Opinion Forum for MSD, have received travel fees from AstraZeneca, Abbott, Astellas, and Novartis, have served as a remunerated advisory board member for Mundipharma and have attended remunerated speaker meetings for GSK and Novartis.

Additional information

Funding

This paper received no funding.